💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Chlorpropamide

CHEMBL498 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
276.7 g/mol
LogP
2.3
Phase
4

A first-generation sulfonylurea oral antidiabetic drug that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. It has an unusually long half-life that allows once-daily dosing but also increases the risk of prolonged hypoglycemia. It has largely been replaced by second-generation sulfonylureas and newer drug classes due to its side effect profile.

น้ำหนักโมเลกุล

276.7400 g/mol

LogP

2.30

TPSA

83.70 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Cardiovascular Disease Type 2 Diabetes

กลไกการออกฤทธิ์

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)

                

                

                

                    
                    

                        
Molecular Formula

                        
C10H13ClN2O3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
พันธะที่หมุนได้

                        
4

                    

                    
                    
                    

                        
อะตอมหนัก

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A first-generation sulfonylurea oral antidiabetic drug that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels. It has an unusually long half-life that allows once-daily dosing but also increases the risk of prolonged hypoglycemia. It has largely been replaced by second-generation sulfonylureas and newer drug classes due to its side effect profile.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Chlorpropamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL498.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2727.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.